Practical management of bleeding in patients receiving non-vitamin K antagonist oral anticoagulants

Summary

Non-vitamin K antagonist oral anticoagulants (NOACs) are increasingly used in the prevention and treatment of venous thromboembolism and in the prevention of stroke in patients with non-valvular atrial fibrillation. In phase III clinical trials and meta-analyses, the NOACs were at least as effective as vitamin K antagonists (VKAs) and were associated with a similar or lower incidence of major bleeding, including consistent and significant decreases in intracranial bleeding, although with an increase in gastrointestinal bleeding for some agents compared with VKAs. Subsequent real-world evidence supports these outcomes. Despite this, physicians have concerns about serious bleeding or emergencies because there are no specific reversal agents for the NOACs. However, in clinical trials, patients receiving NOACs generally had similar or better outcomes after these events than those taking VKAs. As with any bleeding, anticoagulant-related bleeding should first be stratified according to severity and location; risk can be minimised by ongoing assessment. Management protocols for NOAC-related bleeding are similar to those for VKAs but should take into account the pharmacological profile of the specific drug. Because of their short half-lives, NOAC-related mild bleeding can often be controlled by temporarily withholding treatment. More severe bleeding requires standard escalating haemodynamic support measures, and non-specific reversal agents can be considered in life-threatening situations, based on limited clinical data. Specific and rapid reversal agents are not currently available for any oral anticoagulant and restoration of coagulation may not necessarily lead to better outcomes. Nevertheless, specific NOAC reversal agents are in development and show promise in healthy volunteers.

Keywords

Bleeding profiles - bleeding management - non-vitamin K oral anticoagulant - real-world data - reversal agent

• References

• 1 Eikelboom JW, Weitz JI. New anticoagulants. Circulation 2010; 121: 1523-1532.
• 2 Molteni M, Cimminiello C. Warfarin and atrial fibrillation: from ideal to real the warfarin affaire. Thromb J 2014; 12: 5.
• 3 Agnelli G. et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 2013; 369: 799-808.
• 4 The Hokusai-VTE Investigators. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med 2013; 369: 1406-1415.
• 5 Prins MH. et al. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thromb J 2013; 11: 21.
• 6 Schulman S. et al. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation 2014; 129: 764-772.
• 7 Patel MR. et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365: 883-891.
• 8 Connolly SJ. et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-1151.
• 9 Connolly SJ. et al. Newly identified events in the RE-LY trial. N Engl J Med 2010; 363: 1875-1876.
• 10 Connolly SJ. et al. Additional events in the RE-LY trial. N Engl J Med 2014; 371: 1464-1465.
• 11 Granger CB. et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365: 981-992.
• 12 Giugliano RP. et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013; 369: 2093-2104.
• 13 Larsen TB. et al. Bleeding events among new starters and switchers to dabigatran compared with warfarin in atrial fibrillation. Am J Med 2014; 127: 650-656.
• 14 Beyer-Westendorf J. et al. Rates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAC registry. Blood 2014; 124: 955-962.
• 15 Hess PL. et al. Addressing barriers to optimal oral anticoagulation use and persistence among patients with atrial fibrillation: Proceedings, Washington, DC, December 3–4, 2012. Am Heart J 2014; 168: 239-247.
• 16 Fox BD. et al. Efficacy and safety of novel oral anticoagulants for treatment of acute venous thromboembolism: direct and adjusted indirect meta-analysis of randomised controlled trials. Br Med J 2012; 345: e7498.
• 17 van der Hulle T. et al. Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and meta-analysis. J Thromb Hae-most 2014; 12: 320-328.
• 18 Castellucci LA. et al. Clinical and safety outcomes associated with treatment of acute venous thromboembolism: a systematic review and meta-analysis. J Am Med Assoc 2014; 312: 1122-1135.
• 19 Kang N, Sobieraj DM. Indirect treatment comparison of new oral anticoagulants for the treatment of acute venous thromboembolism. Thromb Res 2014; 133: 1145-1151.
• 20 Mantha S, Ansell J. Indirect comparison of dabigatran, rivaroxaban, apixaban and edoxaban for the treatment of acute venous thromboembolism. J Thromb Thrombol 2015; 39: 155-165.
• 21 Schulman S. et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009; 361: 2342-2352.
• 22 The EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010; 363: 2499-2510.
• 23 The EINSTEIN–PE Investigators. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012; 366: 1287-1297.
• 24 Agnelli G. et al. Apixaban for extended treatment of venous thromboembolism. N Engl J Med 2013; 368: 699-708.
• 25 Schulman S. et al. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med 2013; 368: 709-718.
• 26 Camm AJ. et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 2012; 33: 2719-2747.
• 27 January CT. et al. 2014 AHA/ACC/HRS Guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 2014; 64: e1-e76.
• 28 Chatterjee S. et al. New oral anticoagulants and the risk of intracranial hemorrhage: traditional and Bayesian meta-analysis and mixed treatment comparison of randomized trials of new oral anticoagulants in atrial fibrillation. J Am Med Assoc Neurol 2013; 70: 1486-1490.
• 29 Ruff CT. et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014; 383: 955-962.
• 30 Miller CS. et al. Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation. Am J Cardiol 2012; 110: 453-460.
• 31 Lip GYH. et al. Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation. J Am Coll Cardiol 2012; 60: 738-746.
• 32 Fang MC. et al. Death and disability from warfarin-associated intracranial and extracranial hemorrhages. Am J Med 2007; 120: 700-705.
• 33 Vanassche T. et al. Organ-specific bleeding patterns of anticoagulant therapy: lessons from clinical trials. Thromb Haemost 2014; 112: 918-923.
• 34 The Stroke Risk in Atrial Fibrillation Working Group. Independent predictors of stroke in patients with atrial fibrillation: a systematic review. Neurology 2007; 69: 546-554.
• 35 Hylek EM. Contra: ’Warfarin should be the drug of choice for thromboprophylaxis in elderly patients with atrial fibrillation’. Caveats regarding use of oral anticoagulant therapy among elderly patients with atrial fibrillation. Thromb Haemost 2008; 100: 16-17.
• 36 Halperin JL. et al. Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the Rivaroxaban Once daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF). Circulation 2014; 130: 138-146.
• 37 Halvorsen S. et al. Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial. Eur Heart J 2014; 35: 1864-1872.
• 38 Eikelboom JW. et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation 2011; 123: 2363-2372.
• 39 Sardar P. et al. Novel oral anticoagulants in patients with renal insufficiency: a meta-analysis of randomized trials. Can J Cardiol 2014; 30: 888-897.
• 40 Lega JC. et al. Consistency of safety profile of new oral anticoagulants in patients with renal failure. J Thromb Haemost 2014; 12: 337-343.
• 41 Prandoni P. et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 2002; 100: 3484-3488.
• 42 Prins MH. et al. Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a pooled subgroup analysis of two randomised controlled trials. Lancet Haematol 2014; 01: e37-e46.
• 43 Vedovati MC. et al. Direct oral anticoagulants in patients with VTE and cancer: a systematic review and meta-analysis. Chest 2015; 147: 475-483.
• 44 Davidson BL. et al. Bleeding risk of patients with acute venous thromboembolism taking nonsteroidal anti-inflammatory drugs or aspirin. J Am Med Assoc Intern Med 2014; 174: 947-953.
• 45 Dans AL. et al. Concomitant Use of Antiplatelet Therapy with Dabigatran or Warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Trial. Circulation 2013; 127: 634-640.
• 46 Tamayo S. et al. Characterizing major bleeding in patients with nonvalvular atrial fibrillation: a pharmacovigilance study of 27 467 patients taking rivaroxaban. Clin Cardiol 2015; 38: 63-68.
• 47 Larsen TB. et al. Efficacy and safety of dabigatran etexilate and warfarin in “real-world” patients with atrial fibrillation: a prospective nationwide cohort study. J Am Coll Cardiol 2013; 61: 2264-2273.
• 48 Fontaine GV. et al. Major bleeding with dabigatran and rivaroxaban in patients with atrial fibrillation: a real-world setting. Clin Appl Thromb Hemost 2014; 20: 665-672.
• 49 Food and Drug Administration. FDA Drug Safety Communication: FDA study of Medicare patients finds risks lower for stroke and death but higher for gastrointestinal bleeding with Pradaxa (dabigatran) compared to warfarin. Available at: http://www.fda.gov/Drugs/DrugSafety/ucm396470.htm Accessed December 19, 2014.
• 50 Graham DJ. et al. Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for non-valvular atrial fibrillation. Circulation 2015; 131: 157-164.
• 51 Southworth MR. et al. Dabigatran and postmarketing reports of bleeding. N Engl J Med 2013; 368: 1272-1274.
• 52 Food and Drug Administration. FDA Drug Safety Communication: Update on the risk for serious bleeding events with the anticoagulant Pradaxa. Available at: http://www.fda.gov/Drugs/DrugSafety/ucm326580.htm Accessed March 2, 2015.
• 53 Food and Drug Administration. FDA News release. FDA approves Eliquis to reduce the risk of stroke, blood clots in patients with non-valvular atrial fibrillation. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm333634.htm Accessed March 2, 2015.
• 54 Kakkar AK. et al. Risk profiles and antithrombotic treatment of patients newly diagnosed with atrial fibrillation at risk of stroke: perspectives from the international, observational, prospective GARFIELD Registry. PLoS One 2013; 08: e63479.
• 55 Haas S. et al. International normalized ratio control and 1-year outcomes in patients with newly diagnosed atrial fibrillation: the GARFIELD Registry. Eur Heart J. 2014 35. Abstract P2656.
• 56 Bassand JP. et al. Truly low-risk patients with newly diagnosed non-valvular atrial fibrillation at risk of stroke: 1-year outcomes from the GARFIELD Registry. Eur Heart J. 2014 35. Abstract P2646.
• 57 Huisman MV. et al. Design and rationale of Global Registry on Long-term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation: a global registry program on long-term oral antithrombotic treatment in patients with atrial fibrillation. Am Heart J 2014; 167: 329-334.
• 58 Huisman MV. et al. Antithrombotic treatment pattern and baseline characteristics of dabigatran and vitamin K antagonist cohorts in North America – The GLORIA-AF registry program. Eur Heart J. 2014 35. Abstract P4394.
• 59 Oldgren J. et al. Variations in cause and management of atrial fibrillation in a prospective registry of 15,400 emergency department patients in 46 countries: the RE-LY Atrial Fibrillation Registry. Circulation 2014; 129: 1568-1576.
• 60 Majeed A. et al. Management and outcomes of major bleeding during treatment with dabigatran or warfarin. Circulation 2013; 128: 2325-2332.
• 61 Hylek EM. et al. Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin: The ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation): Predictors, Characteristics, and Clinical Outcomes. J Am Coll Cardiol 2014; 63: 2141-2147.
• 62 Hart RG. et al. Intracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran: the RE-LY trial. Stroke 2012; 43: 1511-1517.
• 63 Hankey GJ. et al. Intracranial hemorrhage among patients with atrial fibrillation anticoagulated with warfarin or rivaroxaban: the rivaroxaban once daily, oral, direct Factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation. Stroke 2014; 45: 1304-1312.
• 64 Healey JS. et al. Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the randomized evaluation of long-term anticoagulation therapy (RE-LY) randomized trial. Circulation 2012; 126: 343-348.
• 65 Sherwood MW. et al. Outcomes of temporary interruption of rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: results from the Rivaroxaban Once daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF). Circulation 2014; 129: 1850-1859.
• 66 Beyer-Westendorf J. et al. Peri-interventional management of novel oral anticoagulants in daily care: results from the prospective Dresden NOAC registry. Eur Heart J 2014; 35: 1888-1896.
• 67 Dowlatshahi D. et al. Poor prognosis in warfarin-associated intracranial hemorrhage despite anticoagulation reversal. Stroke 2012; 43: 1812-1817.
• 68 Majeed A. et al. Mortality in vitamin K antagonist-related intracerebral bleeding treated with plasma or 4-factor prothrombin complex concentrate. Thromb Haemost 2014; 111: 233-239.
• 69 Bayer Pharma AG. Xarelto^® (rivaroxaban) Summary of Product Characteristics. 2015 Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000944/WC500057108.pdf Accessed April 28, 2015.
• 70 Janssen Pharmaceuticals Inc.. Xarelto^® (rivaroxaban) Prescribing Information. 2015 Available at: http://www.xareltohcp.com/sites/default/files/pdf/xarelto_0.pdf Accessed April 28, 2015.
• 71 Bristol-Myers Squibb, Pfizer. Eliquis^® (apixaban) Summary of Product Characteristics. 2014 Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002148/WC500107728.pdf Accessed April 28, 2015.
• 72 Bristol-Myers Squibb Company, Pfizer Inc.. Eliquis^® (apixaban) Prescribing Information. 2014 Available at: http://packageinserts.bms.com/pi/pi_eliquis.pdf Accessed April 28, 2015.
• 73 Boehringer Ingelheim International GmbH. Pradaxa^® (dabigatran etexilate) Summary of Product Characteristics. 2015 Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000829/WC500041059.pdf Accessed April 28, 2015.
• 74 Boehringer Ingelheim Pharmaceuticals Inc.. Pradaxa^® (dabigatran etexilate) Prescribing Information. 2015 Available at: http://bidocs.boehringer-ingelheim.com/BIWebAccess/ViewServlet.ser?docBase=renetnt&folderPath=/Prescribing%20Information/PIs/Pradaxa/Pradaxa.pdf Accessed April 28, 2015.
• 75 Heidbuchel H. et al. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace 2013; 15: 625-651.
• 76 Pernod G. et al. Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or Factor-Xa inhibitors: proposals of the Working Group on Perioperative Haemostasis (GIHP) – March 2013. Arch Cardiovasc Dis 2013; 106: 382-393.
• 77 Lindhoff-Last E. et al. Laboratory testing of rivaroxaban in routine clinical practice: When, how, and which assays. Ann Med 2013; 45: 423-429.
• 78 Desai J. et al. Gastrointestinal bleeding with the new oral anticoagulants--defining the issues and the management strategies. Thromb Haemost 2013; 110: 205-212.
• 79 Levy JH, Goodnough LT. How I use fibrinogen replacement therapy in acquired bleeding. Blood 2015; 125: 1387-1393.
• 80 Stangier J. et al. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study. Clin Pharmacokinet 2010; 49: 259-268.
• 81 Khadzhynov D. et al. Effective elimination of dabigatran by haemodialysis. A phase I single-centre study in patients with end-stage renal disease. Thromb Haemost 2013; 109: 596-605.
• 82 Marlu R. et al. Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban. A randomised crossover ex vivo study in healthy volunteers. Thromb Haemost 2012; 108: 217-224.
• 83 Khoo TL. et al. The use of FEIBA(R) in the correction of coagulation abnormalities induced by dabigatran. Int J Lab Hematol 2013; 35: 222-224.
• 84 Escolar G. et al. Reversal of apixaban induced alterations in hemostasis by different coagulation factor concentrates: significance of studies in vitro with circulating human blood. PLoS One 2013; 08: e78696.
• 85 Körber MK. et al. Measurement and reversal of prophylactic and therapeutic peak levels of rivaroxaban: an in vitro study. Clin Appl Thromb Hemost 2014; 20: 735-740.
• 86 Martin AC. et al. Multimodal assessment of non-specific hemostatic agents for apixaban reversal. J Thromb Haemost 2015; 13: 426-436.
• 87 Pragst I. et al. Reversal of dabigatran anticoagulation by prothrombin complex concentrate (Beriplex P/N) in a rabbit model. J Thromb Haemost 2012; 10: 1841-1848.
• 88 Godier A. et al. Evaluation of prothrombin complex concentrate and recombinant activated Factor VII to reverse rivaroxaban in a rabbit model. Anesthesiology 2012; 116: 94-102.
• 89 Lambourne MD. et al. Prothrombin complex concentrates reduce blood loss in murine coagulopathy induced by warfarin, but not in that induced by dabigatran etexilate. J Thromb Haemost 2012; 10: 1830-1840.
• 90 Perzborn E. et al. Reversal of rivaroxaban anticoagulation by haemostatic agents in rats and primates. Thromb Haemost 2013; 110: 162-172.
• 91 Martin AC. et al. Evaluation of recombinant activated Factor VII, prothrombin complex concentrate, and fibrinogen concentrate to reverse apixaban in a rabbit model of bleeding and thrombosis. Int J Cardiol 2013; 168: 4228-4233.
• 92 Zhou W. et al. Hemostatic therapy in experimental intracerebral hemorrhage associated with rivaroxaban. Stroke 2013; 44: 771-778.
• 93 Grottke O. et al. Prothrombin complex concentrates and a specific antidote to dabigatran are effective ex-vivo in reversing the effects of dabigatran in an anti-coagulation/liver trauma experimental model. Crit Care 2014; 18: R27.
• 94 Honickel M. et al. Reversal of dabigatran anticoagulation ex vivo: Porcine study comparing prothrombin complex concentrates and idarucizumab. Thromb Haemost 2015; 113: 728-740.
• 95 Eerenberg ES. et al. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation 2011; 124: 1573-1579.
• 96 Levi M. et al. Comparison of three- and four-factor prothrombin complex concentrates on the anticoagulant effects of rivaroxaban in healthy volunteers. J Thromb Haemost 2014; 12: 1428-1436.
• 97 Perlstein I. et al. Incidence and outcomes of gastrointestinal hemorrhage in patients with atrial fibrillation treated with rivaroxaban or warfarin: results from the ROCKET AF trial. Blood 2014; 124: 345.
• 98 Zahir H. et al. Edoxaban effects on bleeding following punch biopsy and reversal by a 4-factor prothrombin complex concentrate. Circulation 2015; 131: 82-90.
• 99 Dusel CH. et al. Identification of prothrombin as a major thrombogenic agent in prothrombin complex concentrates. Blood Coagul Fibrinolysis 2004; 15: 405-411.
• 100 Grottke O. et al. Increasing concentrations of prothrombin complex concentrate induce disseminated intravascular coagulation in a pig model of coagulopathy with blunt liver injury. Blood 2011; 118: 1943-1951.
• 101 Piccini JP. et al. Management of major bleeding events in patients treated with rivaroxaban vs. warfarin: results from the ROCKET AF trial. Eur Heart J 2014; 35: 1873-1880.
• 102 Baumann Kreuziger LM, Reding MT. Management of bleeding associated with dabigatran and rivaroxaban: a survey of current practices. Thromb Res 2013; 132: e161-e163.
• 103 Lu G. et al. A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation Factor Xa. Nat Med 2013; 19: 446-451.
• 104 Crowther M. et al. A phase 2 randomized, double-blind, placebo-controlled trial demonstrating reversal of rivaroxaban-induced anticoagulation in healthy subjects by andexanet alfa (PRT064445), an antidote for FXa inhibitors. Blood (ASH Annual Meeting Abstracts). 2013 122. Abstract 3636.
• 105 Crowther M. et al. A phase 2 randomized, double-blind, placebo-controlled trial of PRT064445, a novel, universal antidote for direct and indirect Factor Xa inhibitors. J Thromb Haemost. 2013 11. Abstract AS 20.1.
• 106 Crowther M. et al. ANNEXA-A: a phase 3 randomized, double-blind, placebo-controlled trial, demonstrating reversal of apixaban-induced anticoagulation in older subjects by andexanet alfa (PRT064445), a universal antidote for Factor Xa (fXa) inhibitors. Circulation. 2014 130. Abstract 2116.
• 107 Gold MA. et al. ANNEXA-R: a phase 3 randomized, double-blind, placebo-controlled trial, demonstrating reversal of rivaroxaban-induced anticoagulation in older subjects by andexanet alfa (PRT064445), a universal antidote for Factor Xa (FXa) inhibitors. J Am Coll Cardiol. 2015 65. Abstract A23.
• 108 Schiele F. et al. A specific antidote for dabigatran: functional and structural characterization. Blood 2013; 121: 3554-3562.
• 109 Glund S. et al. A specific antidote for dabigatran: immediate, complete and sustained reversal of dabigatran induced anticoagulation in healthy male volunteers. Circulation. 2013 128. Abstract A17765.
• 110 Glund S. et al. Idarucizumab, a specific antidote for dabigatran: immediate, complete and sustained reversal of dabigatran induced anticoagulation in elderly and renally impaired subjects. Blood 2014; 124: 344.
• 111 Pollack Jr CV. et al. Idarucizumab for dabigatran reversal. N Engl J Med. 2015 Epub ahead of print.
• 112 Ansell JE. et al. Aripazine reverses unfractionated and low molecular weight heparins, fondaparinux and new Xa and IIa oral anticoagulants: report of Phase I/II clinical trial with edoxaban. Eur Heart J. 2014 35. Abstract A4766.
• 113 Makris M. et al. Guideline on the management of bleeding in patients on anti-thrombotic agents. Br J Haematol 2012; 160: 35-46.
• 114 Peacock WF. et al. Emergency management of bleeding associated with old and new oral anticoagulants. Clin Cardiol 2012; 35: 730-737.
• 115 Nessel C. et al. Incidence and outcomes of gastrointestinal hemorrhage in patients with atrial fibrillation treated with rivaroxaban or warfarin: results from the ROCKET AF trial. Chest 2012; 142: 84A-84A.
• 116 Beyer-Westendorf J. et al. Real life efficacy and safety of dabigatran for stroke prevention in atrial fibrillation: updated results of the prospective NOAC registry (NCT01588119). Eur Heart J. 2013 34. Abstract 4871.
• 117 Sørensen R. et al. Dabigatran use in Danish atrial fibrillation patients in 2011: a nationwide study. Br Med J Open. 2013 03.
• 118 Vaughan Sarrazin MS. et al. Bleeding rates in Veterans Affairs patients with atrial fibrillation who switch from warfarin to dabigatran. Am J Med 2014; 127: 1179-1185.
• 119 Hernandez I. et al. Risk of bleeding with dabigatran in atrial fibrillation. J Am Med Assoc Intern Med 2015; 175: 18-24.
• 120 Crowther M. et al. Reversal of enoxaparin-induced anticoagulation in healthy subjects by andexanet alfa (PRT064445), an antidote for direct and indirect fXa inhibitors – a phase 2 randomized, double-blind, placebo-controlled trial. J Thromb Haemost. 2014 12. Abstract COA01.